Aurinia Pharm Ord AUPH

$16.51 -0.22 (-1.31%)

Valuation

Market cap
2,196,672,000
Revenue TTM
$283,060,000
Net income TTM
$287,200,000
PE ratio
16.40
Forward PE
18.59
Profit margin
101.46%
Debt to equity
0.00

Trading

Volume
737,500
Avg volume
918,434
Day's range
$16.35 – $16.81
Shares out
133,051,000
Stochastic %K
57%
Beta
1.60
Analysts
Strong Sell
Price target
$17.75

Price

Company profile

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducin...

Show more

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
250 744 2487
Website
https://www.auriniapharma.com
Address
#140, 14315 – 118 Avenue, Edmonton, Canada

Latest news

Stocktwits

Auphiliate Oct 18, 11:44 PM
$AUPH Days to October 23rd, deadline for infringing parties to file claim construction briefs! 😁
0 replies
MarginMonster Oct 18, 5:18 PM
$AUPH Maybe this needs a little more time before it makes sense.
0 replies
jdoldnumber7 Oct 18, 4:09 PM
$AUPH Stone crab season is now open in Florida! Bumper season.
0 replies
Solomonwisdom7 Oct 18, 12:19 AM
$AUPH e-mail him again and ask him who his suitors are for a BO?
1 replies
Doozio Oct 17, 2:35 PM
$XBI it $AUPH to be. Until it isn’t. Bahhht for $NOW it still is.
1 replies
SuperGreenToday Oct 17, 2:14 AM
$AUPH Share Price: $16.52 Contract Selected: Jan 21, 2028 $15 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.85 – $4.70 Potential Upside: 71% ROI Time to Expiration: 461 Days | Updates via https://fxcapta.com/stockinfo/
1 replies
VolumeSpreadAnalysis Oct 16, 10:56 PM
$AUPH Price: $N/A Volume: Average Catalyst: Ongoing Lupkynis sales growth and pipeline updates on voclosporin/povetacicept trials continue to drive investor sentiment. Resistance: $12.50 Support: $9.80 Bull case: A break above resistance on strong volume could signal momentum toward retesting recent highs as revenue growth accelerates. Bear case: Failure to hold support may trigger a slide back toward the low single digits if guidance disappoints or trial data stalls. What I'm watching: Watching for a volume surge to confirm direction and holding above support as a sign of underlying strength. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio: @VolumeSpreadAnalysis
0 replies
ProGuy626 Oct 16, 8:15 PM
$AUPH Just because patent is granted doesn’t mean they can use it off label or sell as a treatment. AUPH still has to conduct clinical trials.
0 replies